MA45862A - Combinaison d'inhibiteurs du protéasome et d'anticorps anti-cd30 - Google Patents

Combinaison d'inhibiteurs du protéasome et d'anticorps anti-cd30

Info

Publication number
MA45862A
MA45862A MA045862A MA45862A MA45862A MA 45862 A MA45862 A MA 45862A MA 045862 A MA045862 A MA 045862A MA 45862 A MA45862 A MA 45862A MA 45862 A MA45862 A MA 45862A
Authority
MA
Morocco
Prior art keywords
antibodies
combination
proteasome inhibitors
proteasome
inhibitors
Prior art date
Application number
MA045862A
Other languages
English (en)
Inventor
Nibedita Chattopadhyay
Dirk Huebner
Sakeena Syed
Original Assignee
Millennium Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharm Inc filed Critical Millennium Pharm Inc
Publication of MA45862A publication Critical patent/MA45862A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/22—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
MA045862A 2016-08-04 2017-08-03 Combinaison d'inhibiteurs du protéasome et d'anticorps anti-cd30 MA45862A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662370812P 2016-08-04 2016-08-04

Publications (1)

Publication Number Publication Date
MA45862A true MA45862A (fr) 2021-05-05

Family

ID=61074014

Family Applications (1)

Application Number Title Priority Date Filing Date
MA045862A MA45862A (fr) 2016-08-04 2017-08-03 Combinaison d'inhibiteurs du protéasome et d'anticorps anti-cd30

Country Status (7)

Country Link
US (1) US20190192559A1 (fr)
EP (1) EP3493793A4 (fr)
JP (1) JP2019524780A (fr)
CN (1) CN109562084A (fr)
CA (1) CA3032011A1 (fr)
MA (1) MA45862A (fr)
WO (1) WO2018027022A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116964098A (zh) 2021-03-01 2023-10-27 南特生物公司 抗cd30单克隆抗体和嵌合抗原受体

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2007003533A (es) * 2004-10-01 2007-05-23 Medarex Inc Metodos de tratar linfomas cd30 positivas.
SI2318419T2 (sl) * 2008-06-17 2025-10-30 Takeda Pharmaceutical Company Limited Spojine boronat estra in njihovi farmacevtski sestavki
JP6121906B2 (ja) * 2010-10-22 2017-04-26 シアトル ジェネティクス,インコーポレーテッド アウリスタチン系抗体薬物複合体とPI3K−AKTmTOR経路インヒビターの間の相乗効果
US10335494B2 (en) * 2013-12-06 2019-07-02 Millennium Pharmaceuticals, Inc. Combination of aurora kinase inhibitors and anti-CD30 antibodies
UA121389C2 (uk) * 2014-05-20 2020-05-25 Мілленніум Фармасьютікалз, Інк. Борвмісні інгібітори протеасом для застосування після первинної протиракової терапії

Also Published As

Publication number Publication date
JP2019524780A (ja) 2019-09-05
CN109562084A (zh) 2019-04-02
EP3493793A4 (fr) 2020-04-01
WO2018027022A1 (fr) 2018-02-08
US20190192559A1 (en) 2019-06-27
CA3032011A1 (fr) 2018-02-08
EP3493793A1 (fr) 2019-06-12

Similar Documents

Publication Publication Date Title
MA50359A (fr) Anticorps anti-cd38 et procédés d'utilisation
MA42043A (fr) Anticorps anti-ox40 et procédés d'utilisation de ceux-ci
MA50956A (fr) Anticorps anti-cd137 et procédés d'utilisation correspondants
EP3581651A4 (fr) Anticorps anti-gprc5d et molécule le contenant
MA42925A (fr) Anticorps anti-tigit et méthodes d'utilisation
MA51552A (fr) Anticorps anti-ox40 et procédés d'utilisation
EP3618871A4 (fr) Formulations d'anticorps anti-lag3 etco-formulations d'anticorps anti-lag3 et d'anticorps anti-pd-1
EP3626825A4 (fr) Anticorps anti-cdh6 et conjugué anticorps anti-cdh6-médicament
MA44990A (fr) Polythérapies d'inhibiteurs de hdac et d'inhibiteurs de pd-l1
MA50948A (fr) Anticorps et procédés d'utilisation de ceux-ci
EP3383914A4 (fr) Anticorps anti-ox40 et leurs procédés d'utilisation
MA45123A (fr) Anticorps anti-tim-3 et leurs méthodes d'utilisation
MA43018A (fr) Anticorps anti-pd1 et procédés d'utilisation
EP3472200A4 (fr) Anticorps anti-myostatine et leurs procédés d'utilisation
MA47849A (fr) Anticorps anti-gitr et leurs procédés d'utilisation
EP3525583A4 (fr) Anticorps anti-c1s et leurs méthodes d'utilisation
EP3436476A4 (fr) Anticorps anti-ryk et leurs procédés d'utilisation
EP3731867A4 (fr) Anticorps anti-lrp5/6 et leurs procédés d'utilisation
EP3408284A4 (fr) Détection d'un anticorps dirigé contre un agent pathogène
EP3302561A4 (fr) Combinaisons d'immunoconjugués anti-cd37 et d'anticorps anti-cd20
EP3328429A4 (fr) Peptides et anticorps pour l'élimination de biofilms
EP3710589A4 (fr) Anticorps anti-c1s et procédés d'utilisation
MA43385A (fr) Nouveaux anticorps anti-claudine et méthodes d'utilisation
TWD187904S (zh) 追蹤裝置
EP3394098A4 (fr) Anticorps anti-myostatine et procédés d'utilisation